Literature DB >> 9853979

Modeling INR data to predict maintenance fluindione dosage.

E Comets1, F Mentré, F Pousset, B Diquet, G Montalescot, A Ankri, A Mallet, P Lechat.   

Abstract

This study was designed to construct a pharmacokinetic/pharmacodynamic model describing the evolution of International Normalized Ratio (INR) under oral anticoagulation treatment by fluindione in patients and to develop a method for individualization of fluindione dosage. Three indirect response models describing the concentration-INR relationship were tested using a nonparametric estimation method. INR was modelled as a quantity being produced and eliminated. According to a log-likelihood ratio test, the evolution of INR was best modelled as an inhibition of its elimination by fluindione. The selected model was evaluated in 24 additional patients with INR measurements (after 2, 3, 4, 6, and 10 doses). Using a Bayesian method with data until day 4, INR was correctly predicted for days 6 and 10. The population characteristics of fluindione were estimated, pooling the two groups of patients. A Bayesian method for individualization of dosage regimen was developed, based on a risk function for INR at steady state. Prescription rules for fluindione were derived using this method retrospectively on the 73 patients in this study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853979     DOI: 10.1097/00007691-199812000-00009

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  Pharmacokinetic and pharmacodynamic variability of fluindione in octogenarians.

Authors:  E Comets; B Diquet; S Legrain; M-G Huisse; A Godon; C Bruhat; M-P Chauveheid; S Delpierre; X Duval; G Berrut; C Verstuyft; M-C Aumont; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-05       Impact factor: 6.875

3.  Weighted target interval stochastic control methods with global optimization and their applications in individualizing therapy.

Authors:  Shaolin Ji; Yingzhi Zeng; Ping Wu; Edmund Jon Deoon Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-12       Impact factor: 2.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.